Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

Peter A Fasching,1 Thomas E Delea,2 Yen-Shen Lu,3 Richard De Boer,4 Sara A Hurvitz,5 Aaron Moynahan,2 David Chandiwana,6 Brad Lanoue,6 Huilin Hu,6 Astrid Thuerigen,7 Joyce O’Shaughnessy8 1University Hospital Erlangen, Comprehensive Cancer Center Erlangen—EMN, Department of Gynecology and Obstetrics,...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Dove Medical Press 2021-11-01
Ráidu:	Cancer Management and Research
Fáttát:	monaleesa-3 paloma-1 overall survival cdk4/6 inhibitor
Liŋkkat:	https://www.dovepress.com/matching-adjusted-indirect-comparison-of-ribociclib-plus-fulvestrant-v-peer-reviewed-fulltext-article-CMAR
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!